Rainer Tuominen

1.3k citations

31 papers · 640 indexed · h-index 16

Co-authors: Veronica Höiom Johan Hansson Hildur Helgadóttir Håkan Olsson Suzanne Egyházi Brage Göran Jönsson Suzanne Egyházi Joakim Lundeberg
Topics: Melanoma and MAPK Pathways (16 papers)Cutaneous Melanoma Detection and Management (16 papers)Cancer Immunotherapy and Biomarkers (7 papers)
Cited by: Oncology Cancer Research Molecular Biology
Journals: JNCI Journal of the National Cancer Institute Scientific Reports Annals of Oncology
Partner nations: Sweden United Kingdom United States

In The Last Decade

Rainer Tuominen

29 papers receiving 631 citations

Peers

Countries citing papers authored by Rainer Tuominen

Since Specialization

Citations

This map shows the geographic impact of Rainer Tuominen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rainer Tuominen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rainer Tuominen more than expected).

Fields of papers citing papers by Rainer Tuominen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rainer Tuominen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rainer Tuominen. The network helps show where Rainer Tuominen may publish in the future.

Co-authorship network of co-authors of Rainer Tuominen

This figure shows the co-authorship network connecting the top 25 collaborators of Rainer Tuominen. A scholar is included among the top collaborators of Rainer Tuominen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rainer Tuominen. Rainer Tuominen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Coexpression of MTH1 and PMS2 Is Associated with Advanced Disease and Disease Progression after Therapy in Melanoma 2021 ·Journal of Investigative Dermatology ·Ishani Das,Rainer Tuominen,Thomas Helleday,Johan Hansson,Ulrika Warpman Berglund,Suzanne Egyházi Brage	6
2	Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma 2021 ·Genetics in Medicine ·Muyi Yang,Per Johnsson,Lars Bräutigam,Xiaohong R. Yang,Kim Thrane,Jiwei Gao,Nicholas P. Tobin,Yitian Zhou,Rong Yu,Noémi Nagy,Pär G. Engström,Rainer Tuominen,Hanna Eriksson,Joakim Lundeberg,Margaret A. Tucker,Alisa M. Goldstein,(unknown),Jian Zhao,Yihai Cao,Veronica Höiom	0
3	AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma 2020 ·Cell Death and Differentiation ·Ishani Das,Helge Gad,Lars Bräutigam,(unknown),Rainer Tuominen,Veronica Höiom,Ingrid Almlöf,(unknown),Johan Hansson,Thomas Helleday,Suzanne Egyházi Brage,Ulrika Warpman Berglund	21
4	Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma 2020 ·Cell Death and Disease ·Ishani Das,Huiqin Chen,Gianluca Maddalo,Rainer Tuominen,Vito W. Rebecca,Meenhard Herlyn,Johan Hansson,Michael A. Davies,Suzanne Egyházi Brage	14
5	Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status 2019 ·Cell Death and Disease ·Ishani Das,Margareta Wilhelm,Veronica Höiom,(unknown),Fernanda Costa Svedman,Johan Hansson,Rainer Tuominen,Suzanne Egyházi Brage	20
6	Targeting CDK 2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors 2018 ·Molecular Systems Biology ·Alireza Azimi,Stefano Caramuta,Brinton Seashore‐Ludlow,Johan Boström,Jonathan L. Robinson,Fredrik Edfors,Rainer Tuominen,Kristel Kemper,Oscar Krijgsman,Daniel S. Peeper,Jens Nielsen,Johan Hansson,Suzanne Egyházi Brage,Mikael Altun,Mathias Uhlén,Gianluca Maddalo	55
7	1180 Effects of MTH1 inhibitor TH1579 on cutaneous melanoma 2018 ·Journal of Investigative Dermatology ·Ishani Das,Helge Gad,(unknown),Lars Bräutigam,Rainer Tuominen,Thomas Helleday,Johan Hansson,Suzanne Egyházi Brage,Ulrika Warpman Berglund	2
8	Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma 2017 ·BMC Cancer ·(unknown),Hemming Johansson,Rainer Tuominen,Marianne Frostvik Stolt,Johan Hansson,Søren Brage	7
9	Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells 2017 ·Cell Death and Disease ·Alireza Azimi,Rainer Tuominen,Fernanda Costa Svedman,Stefano Caramuta,Maria Pernemalm,Marianne Frostvik Stolt,Lena Kanter,Pedram Kharaziha,Janne Lehtiö,Carolina Johansson,Veronica Höiom,Johan Hansson,Suzanne Egyházi Brage	30
10	Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status 2017 ·Journal of the American Academy of Dermatology ·Hildur Helgadóttir,Rainer Tuominen,Håkan Olsson,Johan Hansson,Veronica Höiom	29
11	GermlineCDKN2AMutation Status and Survival in Familial Melanoma Cases 2016 ·JNCI Journal of the National Cancer Institute ·Hildur Helgadóttir,Veronica Höiom,Rainer Tuominen,K. Nielsen,Göran Jönsson,Håkan Olsson,Johan Hansson	47
12	MGMT promoter methylation is associated with temozolomide response and prolonged progression‐free survival in disseminated cutaneous melanoma 2014 ·International Journal of Cancer ·Rainer Tuominen,Rosalyn Jewell,Joost J. van den Oord,Pascal Wolter,Ulrika Stierner,Christer Lindholm,Carolina Johansson,(unknown),Hemming Johansson,Marianne Frostvik Stolt,Christy Walker,Helen Snowden,Julia Newton‐Bishop,Johan Hansson,Suzanne Egyházi Brage	40
13	Hereditary uveal melanoma: A report of a germline mutation in BAP1 2013 ·Genes Chromosomes and Cancer ·Veronica Höiom,Daniel Edsgärd,Hildur Helgadóttir,Hanna Eriksson,Charlotta All‐Ericsson,Rainer Tuominen,Ivayla Ivanova,Joakim Lundeberg,Olof Emanuelsson,Johan Hansson	40
14	High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma 2013 ·Melanoma Research ·(unknown),Joakim Lundeberg,Hemming Johansson,Rainer Tuominen,(unknown),Johan Hansson,Suzanne Egyházi Brage	23
15	Genome‐wide linkage analysis of Swedish families to identify putative susceptibility loci for cutaneous malignant melanoma 2011 ·Genes Chromosomes and Cancer ·Veronica Höiom,Rainer Tuominen,Johan Hansson	7
16	Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma 2008 ·Cancer Immunology Immunotherapy ·C. Christian Johansson,Suzanne Egyházi,Giuseppe Masucci,Helena Harlin,Dimitrios Mougiakakos,Isabel Poschke,Bo Nilsson,(unknown),Rainer Tuominen,(unknown),Marianne Frostvik Stolt,Johan Hansson,Rolf Kiessling	41
17	Amplification of the cyclin D1 locus 11q13 in melanoma metastases: association to cyclin D1 protein expression 2006 ·Melanoma Research ·Rainer Tuominen,(unknown),Suzanne Egyházi	0
18	Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma 2004 ·Melanoma Research ·Peter A. Berg,Ann‐Marie Wennberg,Rainer Tuominen,Birgitta Sander,Barbro Lundh Rozell,Anton Platz,Johan Hansson	29
19	Constitutive CYP1B1 mRNA expression in human blood mononuclear cells in relation to gender, genotype, and environmental factors 2003 ·Environmental Research ·Rainer Tuominen,Margareta Warholm,Lennart Möller,Agneta Rannug	19
20	Susceptibility factors and DNA adducts in peripheral blood mononuclear cells of aluminium smelter workers exposed to polycyclic aromatic hydrocarbons 2002 ·Archives of Toxicology ·Rainer Tuominen,Paweł Baranczewski,Margareta Warholm,Lars Hagmar,Lennart Möller,Agneta Rannug	13

About Rainer Tuominen

Rainer Tuominen is a scholar working on Oncology, Cancer Research and Cell Biology, having authored 31 papers that have together received 640 indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (16 papers), Cutaneous Melanoma Detection and Management (16 papers) and Cancer Immunotherapy and Biomarkers (7 papers). The work is most often cited by research in Oncology (339 citations), Cancer Research (175 citations) and Molecular Biology (375 citations). Rainer Tuominen has collaborated with scholars based in Sweden, United Kingdom and United States. Frequent co-authors include Veronica Höiom, Johan Hansson, Johan Hansson, Hildur Helgadóttir, Håkan Olsson, Suzanne Egyházi Brage, Göran Jönsson, Suzanne Egyházi, Joakim Lundeberg and Marianne Frostvik Stolt. Their work appears in journals such as JNCI Journal of the National Cancer Institute, Scientific Reports and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact